JPH04120008A - New beautifying cosmetic - Google Patents
New beautifying cosmeticInfo
- Publication number
- JPH04120008A JPH04120008A JP24050190A JP24050190A JPH04120008A JP H04120008 A JPH04120008 A JP H04120008A JP 24050190 A JP24050190 A JP 24050190A JP 24050190 A JP24050190 A JP 24050190A JP H04120008 A JPH04120008 A JP H04120008A
- Authority
- JP
- Japan
- Prior art keywords
- glyceric acid
- salt
- cosmetic
- acid
- beautifying
- Prior art date
- Legal status (The legal status is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the status listed.)
- Granted
Links
- 239000002537 cosmetic Substances 0.000 title claims abstract description 15
- RBNPOMFGQQGHHO-UHFFFAOYSA-N -2,3-Dihydroxypropanoic acid Natural products OCC(O)C(O)=O RBNPOMFGQQGHHO-UHFFFAOYSA-N 0.000 claims abstract description 21
- RBNPOMFGQQGHHO-UWTATZPHSA-N D-glyceric acid Chemical compound OC[C@@H](O)C(O)=O RBNPOMFGQQGHHO-UWTATZPHSA-N 0.000 claims abstract description 16
- 150000003839 salts Chemical class 0.000 claims abstract description 10
- 239000004480 active ingredient Substances 0.000 claims abstract 3
- 230000002087 whitening effect Effects 0.000 claims description 13
- 230000008099 melanin synthesis Effects 0.000 abstract description 6
- 201000001441 melanoma Diseases 0.000 abstract description 4
- 238000002156 mixing Methods 0.000 abstract description 3
- 241001465754 Metazoa Species 0.000 abstract description 2
- 244000005700 microbiome Species 0.000 abstract description 2
- 229910052700 potassium Inorganic materials 0.000 abstract description 2
- 229910052708 sodium Inorganic materials 0.000 abstract description 2
- 230000007541 cellular toxicity Effects 0.000 abstract 1
- 239000003814 drug Substances 0.000 abstract 1
- 239000000203 mixture Substances 0.000 description 11
- CIWBSHSKHKDKBQ-JLAZNSOCSA-N Ascorbic acid Chemical compound OC[C@H](O)[C@H]1OC(=O)C(O)=C1O CIWBSHSKHKDKBQ-JLAZNSOCSA-N 0.000 description 10
- 230000000694 effects Effects 0.000 description 10
- 238000004519 manufacturing process Methods 0.000 description 7
- BTWNEJOURYOHME-UHFFFAOYSA-N 1,3-thiazol-2-ylhydrazine Chemical compound NNC1=NC=CS1 BTWNEJOURYOHME-UHFFFAOYSA-N 0.000 description 6
- 239000002211 L-ascorbic acid Substances 0.000 description 6
- XUMBMVFBXHLACL-UHFFFAOYSA-N Melanin Chemical compound O=C1C(=O)C(C2=CNC3=C(C(C(=O)C4=C32)=O)C)=C2C4=CNC2=C1C XUMBMVFBXHLACL-UHFFFAOYSA-N 0.000 description 6
- 229960005070 ascorbic acid Drugs 0.000 description 6
- 238000009472 formulation Methods 0.000 description 6
- 238000012360 testing method Methods 0.000 description 6
- 235000000069 L-ascorbic acid Nutrition 0.000 description 5
- 239000006071 cream Substances 0.000 description 5
- XLYOFNOQVPJJNP-UHFFFAOYSA-N water Chemical compound O XLYOFNOQVPJJNP-UHFFFAOYSA-N 0.000 description 5
- 239000003205 fragrance Substances 0.000 description 4
- RWSXRVCMGQZWBV-WDSKDSINSA-N glutathione Chemical compound OC(=O)[C@@H](N)CCC(=O)N[C@@H](CS)C(=O)NCC(O)=O RWSXRVCMGQZWBV-WDSKDSINSA-N 0.000 description 4
- 239000003921 oil Substances 0.000 description 4
- 239000012071 phase Substances 0.000 description 4
- -1 1,3-butylene glycerinyl glycerin Chemical compound 0.000 description 3
- KWYUFKZDYYNOTN-UHFFFAOYSA-M Potassium hydroxide Chemical compound [OH-].[K+] KWYUFKZDYYNOTN-UHFFFAOYSA-M 0.000 description 3
- DNIAPMSPPWPWGF-UHFFFAOYSA-N Propylene glycol Chemical compound CC(O)CO DNIAPMSPPWPWGF-UHFFFAOYSA-N 0.000 description 3
- HEMHJVSKTPXQMS-UHFFFAOYSA-M Sodium hydroxide Chemical compound [OH-].[Na+] HEMHJVSKTPXQMS-UHFFFAOYSA-M 0.000 description 3
- 239000002253 acid Substances 0.000 description 3
- 239000008346 aqueous phase Substances 0.000 description 3
- 230000000052 comparative effect Effects 0.000 description 3
- 229940057995 liquid paraffin Drugs 0.000 description 3
- 239000006210 lotion Substances 0.000 description 3
- 239000008213 purified water Substances 0.000 description 3
- PUPZLCDOIYMWBV-UHFFFAOYSA-N (+/-)-1,3-Butanediol Chemical compound CC(O)CCO PUPZLCDOIYMWBV-UHFFFAOYSA-N 0.000 description 2
- 206010014970 Ephelides Diseases 0.000 description 2
- LFQSCWFLJHTTHZ-UHFFFAOYSA-N Ethanol Chemical compound CCO LFQSCWFLJHTTHZ-UHFFFAOYSA-N 0.000 description 2
- 108010024636 Glutathione Proteins 0.000 description 2
- PEDCQBHIVMGVHV-UHFFFAOYSA-N Glycerine Chemical compound OCC(O)CO PEDCQBHIVMGVHV-UHFFFAOYSA-N 0.000 description 2
- 208000003351 Melanosis Diseases 0.000 description 2
- 208000012641 Pigmentation disease Diseases 0.000 description 2
- UIIMBOGNXHQVGW-UHFFFAOYSA-M Sodium bicarbonate Chemical compound [Na+].OC([O-])=O UIIMBOGNXHQVGW-UHFFFAOYSA-M 0.000 description 2
- HVUMOYIDDBPOLL-XWVZOOPGSA-N Sorbitan monostearate Chemical compound CCCCCCCCCCCCCCCCCC(=O)OC[C@@H](O)[C@H]1OC[C@H](O)[C@H]1O HVUMOYIDDBPOLL-XWVZOOPGSA-N 0.000 description 2
- 235000021355 Stearic acid Nutrition 0.000 description 2
- 206010042496 Sunburn Diseases 0.000 description 2
- 239000000654 additive Substances 0.000 description 2
- 238000001816 cooling Methods 0.000 description 2
- 231100000433 cytotoxic Toxicity 0.000 description 2
- 230000001472 cytotoxic effect Effects 0.000 description 2
- 239000002552 dosage form Substances 0.000 description 2
- 229960003180 glutathione Drugs 0.000 description 2
- 238000010438 heat treatment Methods 0.000 description 2
- BXWNKGSJHAJOGX-UHFFFAOYSA-N hexadecan-1-ol Chemical compound CCCCCCCCCCCCCCCCO BXWNKGSJHAJOGX-UHFFFAOYSA-N 0.000 description 2
- 239000004615 ingredient Substances 0.000 description 2
- 230000002401 inhibitory effect Effects 0.000 description 2
- 238000000034 method Methods 0.000 description 2
- GLDOVTGHNKAZLK-UHFFFAOYSA-N octadecan-1-ol Chemical compound CCCCCCCCCCCCCCCCCCO GLDOVTGHNKAZLK-UHFFFAOYSA-N 0.000 description 2
- QIQXTHQIDYTFRH-UHFFFAOYSA-N octadecanoic acid Chemical compound CCCCCCCCCCCCCCCCCC(O)=O QIQXTHQIDYTFRH-UHFFFAOYSA-N 0.000 description 2
- OQCDKBAXFALNLD-UHFFFAOYSA-N octadecanoic acid Natural products CCCCCCCC(C)CCCCCCCCC(O)=O OQCDKBAXFALNLD-UHFFFAOYSA-N 0.000 description 2
- SSZBUIDZHHWXNJ-UHFFFAOYSA-N palmityl stearate Chemical compound CCCCCCCCCCCCCCCCCC(=O)OCCCCCCCCCCCCCCCC SSZBUIDZHHWXNJ-UHFFFAOYSA-N 0.000 description 2
- 239000000049 pigment Substances 0.000 description 2
- 239000001587 sorbitan monostearate Substances 0.000 description 2
- 235000011076 sorbitan monostearate Nutrition 0.000 description 2
- 229940035048 sorbitan monostearate Drugs 0.000 description 2
- 239000008117 stearic acid Substances 0.000 description 2
- 230000001629 suppression Effects 0.000 description 2
- QIVUCLWGARAQIO-OLIXTKCUSA-N (3s)-n-[(3s,5s,6r)-6-methyl-2-oxo-1-(2,2,2-trifluoroethyl)-5-(2,3,6-trifluorophenyl)piperidin-3-yl]-2-oxospiro[1h-pyrrolo[2,3-b]pyridine-3,6'-5,7-dihydrocyclopenta[b]pyridine]-3'-carboxamide Chemical compound C1([C@H]2[C@H](N(C(=O)[C@@H](NC(=O)C=3C=C4C[C@]5(CC4=NC=3)C3=CC=CN=C3NC5=O)C2)CC(F)(F)F)C)=C(F)C=CC(F)=C1F QIVUCLWGARAQIO-OLIXTKCUSA-N 0.000 description 1
- 229940058015 1,3-butylene glycol Drugs 0.000 description 1
- VBICKXHEKHSIBG-UHFFFAOYSA-N 1-monostearoylglycerol Chemical compound CCCCCCCCCCCCCCCCCC(=O)OCC(O)CO VBICKXHEKHSIBG-UHFFFAOYSA-N 0.000 description 1
- FKOKUHFZNIUSLW-UHFFFAOYSA-N 2-Hydroxypropyl stearate Chemical compound CCCCCCCCCCCCCCCCCC(=O)OCC(C)O FKOKUHFZNIUSLW-UHFFFAOYSA-N 0.000 description 1
- HIQIXEFWDLTDED-UHFFFAOYSA-N 4-hydroxy-1-piperidin-4-ylpyrrolidin-2-one Chemical compound O=C1CC(O)CN1C1CCNCC1 HIQIXEFWDLTDED-UHFFFAOYSA-N 0.000 description 1
- 229940090248 4-hydroxybenzoic acid Drugs 0.000 description 1
- 241000196324 Embryophyta Species 0.000 description 1
- DGAQECJNVWCQMB-PUAWFVPOSA-M Ilexoside XXIX Chemical compound C[C@@H]1CC[C@@]2(CC[C@@]3(C(=CC[C@H]4[C@]3(CC[C@@H]5[C@@]4(CC[C@@H](C5(C)C)OS(=O)(=O)[O-])C)C)[C@@H]2[C@]1(C)O)C)C(=O)O[C@H]6[C@@H]([C@H]([C@@H]([C@H](O6)CO)O)O)O.[Na+] DGAQECJNVWCQMB-PUAWFVPOSA-M 0.000 description 1
- 239000004166 Lanolin Substances 0.000 description 1
- 239000004264 Petrolatum Substances 0.000 description 1
- 229920003171 Poly (ethylene oxide) Polymers 0.000 description 1
- ZLMJMSJWJFRBEC-UHFFFAOYSA-N Potassium Chemical compound [K] ZLMJMSJWJFRBEC-UHFFFAOYSA-N 0.000 description 1
- PMZURENOXWZQFD-UHFFFAOYSA-L Sodium Sulfate Chemical compound [Na+].[Na+].[O-]S([O-])(=O)=O PMZURENOXWZQFD-UHFFFAOYSA-L 0.000 description 1
- GWEVSGVZZGPLCZ-UHFFFAOYSA-N Titan oxide Chemical compound O=[Ti]=O GWEVSGVZZGPLCZ-UHFFFAOYSA-N 0.000 description 1
- GSEJCLTVZPLZKY-UHFFFAOYSA-N Triethanolamine Chemical compound OCCN(CCO)CCO GSEJCLTVZPLZKY-UHFFFAOYSA-N 0.000 description 1
- 102000003425 Tyrosinase Human genes 0.000 description 1
- 108060008724 Tyrosinase Proteins 0.000 description 1
- DPXJVFZANSGRMM-UHFFFAOYSA-N acetic acid;2,3,4,5,6-pentahydroxyhexanal;sodium Chemical compound [Na].CC(O)=O.OCC(O)C(O)C(O)C(O)C=O DPXJVFZANSGRMM-UHFFFAOYSA-N 0.000 description 1
- 230000000996 additive effect Effects 0.000 description 1
- 230000003698 anagen phase Effects 0.000 description 1
- 230000003796 beauty Effects 0.000 description 1
- 239000000440 bentonite Substances 0.000 description 1
- 229910000278 bentonite Inorganic materials 0.000 description 1
- SVPXDRXYRYOSEX-UHFFFAOYSA-N bentoquatam Chemical compound O.O=[Si]=O.O=[Al]O[Al]=O SVPXDRXYRYOSEX-UHFFFAOYSA-N 0.000 description 1
- 229910021538 borax Inorganic materials 0.000 description 1
- 235000019437 butane-1,3-diol Nutrition 0.000 description 1
- 159000000007 calcium salts Chemical class 0.000 description 1
- 239000001768 carboxy methyl cellulose Substances 0.000 description 1
- 239000004359 castor oil Substances 0.000 description 1
- 235000019438 castor oil Nutrition 0.000 description 1
- 229960000541 cetyl alcohol Drugs 0.000 description 1
- DTPCFIHYWYONMD-UHFFFAOYSA-N decaethylene glycol Polymers OCCOCCOCCOCCOCCOCCOCCOCCOCCOCCO DTPCFIHYWYONMD-UHFFFAOYSA-N 0.000 description 1
- 230000007423 decrease Effects 0.000 description 1
- 230000001419 dependent effect Effects 0.000 description 1
- 235000014113 dietary fatty acids Nutrition 0.000 description 1
- 239000000839 emulsion Substances 0.000 description 1
- 150000002148 esters Chemical class 0.000 description 1
- 238000011156 evaluation Methods 0.000 description 1
- 239000000194 fatty acid Substances 0.000 description 1
- 229930195729 fatty acid Natural products 0.000 description 1
- 150000004665 fatty acids Chemical class 0.000 description 1
- 239000000796 flavoring agent Substances 0.000 description 1
- 235000019634 flavors Nutrition 0.000 description 1
- 235000011187 glycerol Nutrition 0.000 description 1
- ZEMPKEQAKRGZGQ-XOQCFJPHSA-N glycerol triricinoleate Natural products CCCCCC[C@@H](O)CC=CCCCCCCCC(=O)OC[C@@H](COC(=O)CCCCCCCC=CC[C@@H](O)CCCCCC)OC(=O)CCCCCCCC=CC[C@H](O)CCCCCC ZEMPKEQAKRGZGQ-XOQCFJPHSA-N 0.000 description 1
- 239000001963 growth medium Substances 0.000 description 1
- 239000003112 inhibitor Substances 0.000 description 1
- 229940039717 lanolin Drugs 0.000 description 1
- 235000019388 lanolin Nutrition 0.000 description 1
- 239000007788 liquid Substances 0.000 description 1
- 125000002496 methyl group Chemical group [H]C([H])([H])* 0.000 description 1
- 235000010270 methyl p-hydroxybenzoate Nutrition 0.000 description 1
- 239000004292 methyl p-hydroxybenzoate Substances 0.000 description 1
- LXCFILQKKLGQFO-UHFFFAOYSA-N methylparaben Chemical compound COC(=O)C1=CC=C(O)C=C1 LXCFILQKKLGQFO-UHFFFAOYSA-N 0.000 description 1
- 230000003020 moisturizing effect Effects 0.000 description 1
- AYOOGWWGECJQPI-NSHDSACASA-N n-[(1s)-1-(5-fluoropyrimidin-2-yl)ethyl]-3-(3-propan-2-yloxy-1h-pyrazol-5-yl)imidazo[4,5-b]pyridin-5-amine Chemical compound N1C(OC(C)C)=CC(N2C3=NC(N[C@@H](C)C=4N=CC(F)=CN=4)=CC=C3N=C2)=N1 AYOOGWWGECJQPI-NSHDSACASA-N 0.000 description 1
- GOQYKNQRPGWPLP-UHFFFAOYSA-N n-heptadecyl alcohol Natural products CCCCCCCCCCCCCCCCCO GOQYKNQRPGWPLP-UHFFFAOYSA-N 0.000 description 1
- XULSCZPZVQIMFM-IPZQJPLYSA-N odevixibat Chemical compound C12=CC(SC)=C(OCC(=O)N[C@@H](C(=O)N[C@@H](CC)C(O)=O)C=3C=CC(O)=CC=3)C=C2S(=O)(=O)NC(CCCC)(CCCC)CN1C1=CC=CC=C1 XULSCZPZVQIMFM-IPZQJPLYSA-N 0.000 description 1
- 230000009965 odorless effect Effects 0.000 description 1
- FJKROLUGYXJWQN-UHFFFAOYSA-N papa-hydroxy-benzoic acid Natural products OC(=O)C1=CC=C(O)C=C1 FJKROLUGYXJWQN-UHFFFAOYSA-N 0.000 description 1
- 239000008188 pellet Substances 0.000 description 1
- 229940066842 petrolatum Drugs 0.000 description 1
- 235000019271 petrolatum Nutrition 0.000 description 1
- 230000019612 pigmentation Effects 0.000 description 1
- 239000011591 potassium Substances 0.000 description 1
- 229940093625 propylene glycol monostearate Drugs 0.000 description 1
- 239000011734 sodium Substances 0.000 description 1
- 229910000030 sodium bicarbonate Inorganic materials 0.000 description 1
- 235000017557 sodium bicarbonate Nutrition 0.000 description 1
- 235000019812 sodium carboxymethyl cellulose Nutrition 0.000 description 1
- 229920001027 sodium carboxymethylcellulose Polymers 0.000 description 1
- 239000001509 sodium citrate Substances 0.000 description 1
- NLJMYIDDQXHKNR-UHFFFAOYSA-K sodium citrate Chemical compound O.O.[Na+].[Na+].[Na+].[O-]C(=O)CC(O)(CC([O-])=O)C([O-])=O NLJMYIDDQXHKNR-UHFFFAOYSA-K 0.000 description 1
- 229910052938 sodium sulfate Inorganic materials 0.000 description 1
- 235000011152 sodium sulphate Nutrition 0.000 description 1
- 239000004328 sodium tetraborate Substances 0.000 description 1
- 235000010339 sodium tetraborate Nutrition 0.000 description 1
- 238000013112 stability test Methods 0.000 description 1
- 238000003756 stirring Methods 0.000 description 1
- 239000000126 substance Substances 0.000 description 1
- 208000024891 symptom Diseases 0.000 description 1
- 239000000454 talc Substances 0.000 description 1
- 229910052623 talc Inorganic materials 0.000 description 1
- OGIDPMRJRNCKJF-UHFFFAOYSA-N titanium oxide Inorganic materials [Ti]=O OGIDPMRJRNCKJF-UHFFFAOYSA-N 0.000 description 1
Landscapes
- Cosmetics (AREA)
Abstract
Description
【発明の詳細な説明】
（産業上の利用分野）
本発明はグリセリン酸および／またはその塩を含有する
ことを特徴とする新規美白化粧料に関する。DETAILED DESCRIPTION OF THE INVENTION (Industrial Field of Application) The present invention relates to a novel whitening cosmetic characterized by containing glyceric acid and/or a salt thereof.
（従来の技術）
一般にシミ、ソバカス、日焼けなどに見られる皮膚の色
素沈着は、皮膚内に存在するメラニン色素生成細胞が、
メラニン菟素を過剰に生成することが原因とされている
。この色素沈着の予防および治療には、チロシナーゼ活
性阻害剤としてグルタチオン、Ｌ−アスコルビン酸など
の還元性物質が利用されてきた。(Prior art) Skin pigmentation, which is generally seen in spots, freckles, and sunburn, is caused by melanin pigment-producing cells existing within the skin.
It is thought to be caused by excessive production of melanin. To prevent and treat this pigmentation, reducing substances such as glutathione and L-ascorbic acid have been used as tyrosinase activity inhibitors.
（発明が解決しようとしている課題）
しかし、グルタチオンやＬ−アスコルビン酸は、熱や光
などに対して不安定であり、その活性の経時的減少をと
もなう。Ｌ−アスコルビン酸は高級脂肪酸のエステル誘
導体などにして経時安定性を改良しているが、油溶性に
なったり、優れた美白効果が得られないなどの問題点が
ある。(Problems to be Solved by the Invention) However, glutathione and L-ascorbic acid are unstable to heat and light, and their activity decreases over time. Although L-ascorbic acid has been improved in stability over time by being made into an ester derivative of a higher fatty acid, it has problems such as becoming oil-soluble and not being able to provide an excellent whitening effect.
そこで、本発明者らは、これらの問題点を解決すべく鋭
意研究を重ねた結果、動物、植物および微生物等の生体
内に広く分布するグリセリン酸および／またはその塩が
優れた美白効果を有することを発見し、かつ、経時的に
安定であり、製剤化が容易であることから本発明を完成
するに至った。Therefore, as a result of intensive research to solve these problems, the present inventors found that glyceric acid and/or its salts, which are widely distributed in living organisms such as animals, plants, and microorganisms, have an excellent whitening effect. The present invention was completed based on the discovery that it is stable over time and easy to formulate into a formulation.
（課題を解決するための手段）
すなわち１１本発明は、美白効果を有するグリセリン酸
および／またはその塩を配合した新規美白化粧料を提供
するものである。(Means for Solving the Problems) That is, eleventh aspect of the present invention provides a novel whitening cosmetic containing glyceric acid and/or its salt having a whitening effect.
グリセリン酸およびその塩はり、Ｌ体を問わず、市販品
を利用することができる。グリセリン酸の塩としては、
ナトリウム、カリウムおよびカルシウム塩などが挙げら
れる。Commercially available glyceric acid and its salts, regardless of whether they are in the L form, can be used. As a salt of glyceric acid,
Examples include sodium, potassium and calcium salts.
本発明の美白化粧料は、通常の皮膚化粧料および浴剤な
どに配合される。その配合量として、当該化粧料の配合
成分全量を基準として０．００１−１０重量％好ましく
は０．０５−５．０重量％である。The whitening cosmetic composition of the present invention is incorporated into ordinary skin cosmetic compositions, bath additives, and the like. The blending amount is 0.001-10% by weight, preferably 0.05-5.0% by weight, based on the total amount of the ingredients in the cosmetic.
本発明の美白化粧料の剤型は、特に限定されるものでな
く、クリーム状、乳液状、 ローション状等通常の化粧
料の剤型を適用することができる。The dosage form of the whitening cosmetic of the present invention is not particularly limited, and usual cosmetic dosage forms such as cream, milky lotion, and lotion can be used.
（実施例）
次に本発明の代表的な実施例を挙げるが、本発明はこれ
に限定されるものではない。なお、実施例に示す配合量
の部とは重量部を示す。(Example) Next, typical examples of the present invention will be described, but the present invention is not limited thereto. Note that "parts" in the amounts shown in Examples refer to "parts by weight."
実施例−１化粧水
処方
配合量
Ａ）
ＤＬ
グリセリン酸
Ｏｌ
１部
１、３−ブチレングリニール
グリセリン
キサンタンガム
精製水
Ｂ）エタノ−・ル
ｐ−ヒドロシキ安３、香酸メチル
ポリオキシエチレン（４０Ｊ
硬化ヒマシ油
０、 １
香料 適 置端製水
１０．０製造方法“ 成分Ａおよび
成分Ｂをそれぞれ均一に溶解し、混合し製品とする。Example-1 Lotion formulation Amount A) DL Glyceric acid 1 part 1,3-butylene glycerinyl glycerin Oil 0, 1 Fragrance suitable
10.0 Manufacturing method “Component A and component B are each uniformly dissolved and mixed to form a product.
８、 ０
２、 ０
０．２
４５、 １
０、 １
実施例−２
クリーム
処方
Ａ）ステアリン酸
セチルアルコール
ステアリルアルコール
流動パラフィン
ワセリン
配合量
４．０部
３、 ０
１．０
６．５
１０．０
ソルビタンモノステアレート １．５ポリオキシエ
チレン（２５）
モノステアレート ３．Ｏ
Ｂ） １、３−ブチレングリコール ５．０水酸化
カリウム ０．１ＤＬ−グリセリン酸
０． １ｐ−ヒドロシキ安息香酸メチル
０． ２精製水 ６４．
７Ｃ）香料 適 量製造方
法： 油相成分Ａおよび水相成分Ｂをそれぞれ
７５〜８０℃に加熱溶解した後、成分Ａに成分Ｂを加え
て乳化し、冷却途上で成分Ｃを加えて混合し、 ３０℃
まで冷却し製品とする。8, 0 2, 0 0.2 45, 1 0, 1 Example-2 Cream formulation A) Cetyl stearate alcohol Stearyl alcohol Liquid paraffin petrolatum 4.0 parts 3, 0 1.0 6.5 10.0 Sorbitan Monostearate 1.5 Polyoxyethylene (25) Monostearate 3. O B) 1,3-butylene glycol 5.0 Potassium hydroxide 0.1 DL-glyceric acid 0. Methyl 1p-hydroxybenzoate 0. 2 Purified water 64.
7C) Fragrance Appropriate amount Production method: After heating and dissolving oil phase component A and water phase component B at 75 to 80°C, add component B to component A and emulsify it, and add component C while cooling and mix. , 30℃
Cool it until it becomes a product.
実施例−３乳液
処方 配合量Ａ）ステア
リン酸 ５．０部セチルアルコール
５． ０グリセリンモノステアレート
１．３
流動パラフイン ２．０ソルビタンモ
ノステアレート １．５ポリオキシエチレン（１０
）
モノステアレート ３．Ｏ
Ｂ）グリセリン ６． ０ＤＬ−グ
リセリン酸カルシウム ０． １ｐ−ヒドロシキ安息
香酸メチル ０．２精製水
７７．４０）香料 適 量
製造方法： 実施例−１と同様にして製品とする。Example-3 Emulsion formulation Amount A) Stearic acid 5.0 parts Cetyl alcohol 5. 0 Glycerin monostearate 1.3 Liquid paraffin 2.0 Sorbitan monostearate 1.5 Polyoxyethylene (10
) Monostearate 3. OB) Glycerin 6. 0DL-calcium glycerate 0. 1p-Methyl hydroxybenzoate 0.2 Purified water
77.40) Fragrance (appropriate amount) Production method: Prepare a product in the same manner as in Example-1.
実施例−４パック
処方
ＤＬ−グリセリン酸
１、３−ブチレングリコール
グリセリン
ｐ−ヒドロシキ安息香酸メチル
ポリオキシエチレン（４０）
硬化ヒマシ油
配合量
１、 ０部
１０、Ｏ
１５、Ｏ
Ｏ，２
０゜
クエン酸
クエン酸ナトリウム ０．３香料
適 置端製水
７３．８製造方法： 各成分を均一に溶解し製品
とする。Example - 4 pack prescription DL-glyceric acid 1,3-butylene glycol glycerin p-hydroxybenzoic acid methylpolyoxyethylene (40) Hydrogenated castor oil blending amount 1, 0 parts 10, O 15, O O, 2 0゜Citric acid Acid Sodium Citrate 0.3 Flavor
Suitable for water production
73.8 Manufacturing method: Dissolve each component uniformly to form a product.
ファンデーション
実施例−５
処方
１、ＤＬ−グリセリン酸
２、ステアリン酸
３、モノステ°アリン酸
プロピレングリコール
４、七トステアリルアルコール
５、液状ラノリン
６、流動パラフィン
７、 ミリスチン酸イソプロピル
８、ｐ−ヒドロキシ安息香酸ブチル
９、精製水
１０、カルボキシメチルセルロース
ナトリウム
配合量
０．１部
２、 ４
０゜
１１、ベントナイト
０゜
１２、プロピレングリコール ４．０１３、
トリエタノールアミン １．１１４、ｐ−ヒド
ロキシ安息香酸メチル ０．２１５、酸化チタン
８． ０１６、 タルク
４．０１７、着色顔料
５．０１８、香料 適
量製造方法：成分１，９を７０℃に加熱し成分１１を加
えよく膨潤させる。これに成分１２を分散させた成分１
０を加えて溶解し、続いて、成分１３．１４を溶解し水
相とする。成分２〜８を加熱溶解し、８０℃に保ち油相
とする。水相に よく混合し粉砕機に通し粉砕した成分
１７を加え、ホモミキサーでかくはんし７５℃に保つ、
この水相に油相をかきまぜながら加え、冷却し、 ４５
℃で成分１８を加え、か（はん冷却後に製品とする。Foundation Example-5 Formula 1, DL-glyceric acid 2, stearic acid 3, propylene glycol monostearate 4, heptostearyl alcohol 5, liquid lanolin 6, liquid paraffin 7, isopropyl myristate 8, p-hydroxybenzoic acid Butyl 9, Purified water 10, Sodium carboxymethylcellulose blended amount 0.1 part 2, 4 0°11, Bentonite 0°12, Propylene glycol 4.013,
Triethanolamine 1.114, Methyl p-hydroxybenzoate 0.215, Titanium oxide
8. 016, Talc
4.017 Colored pigments
5.018, fragrance suitable
Production method: Heat components 1 and 9 to 70°C, add component 11, and swell well. Component 1 with component 12 dispersed in this
0 is added and dissolved, and then components 13 and 14 are dissolved to form an aqueous phase. Components 2 to 8 are dissolved by heating and kept at 80°C to form an oil phase. Add component 17, which was mixed well and passed through a pulverizer to the aqueous phase, and stirred with a homomixer and kept at 75°C.
Add the oil phase to this aqueous phase while stirring, cool, and
Add component 18 at ℃ and use it as a product after cooling.
実施例−６浴剤
処方
硫酸ナトリウム
配゛合量
４３．０部
炭酸水素ナトリウム ５０．０ＤＬ−グリ
セリン酸カルシウム １．０ホウ砂
２・ ０黄色２０２号の（１）
適 量香料 適 量
製造方法： 各成分をよく混合して製品とする。Example-6 Bath additive formulation Sodium sulfate Amount: 43.0 parts Sodium hydrogen carbonate 50.0 DL - Calcium glycerate 1.0 Borax
2.0 Yellow No. 202 (1)
Appropriate amountFragrance Appropriate amountManufacturing method: Mix each ingredient thoroughly to make the product.
（本発明の効果）
本発明の美泊化粧料は優れたメラニン生成抑制効果およ
び美白効果を有する。(Effects of the present invention) The beauty cosmetics of the present invention have excellent melanin production inhibiting effects and whitening effects.
次に莫験例を挙げて、本発明の美白化粧料をさらに詳し
く説明する。Next, the whitening cosmetic composition of the present invention will be explained in more detail with reference to experimental examples.
冥験例−１
Ｂ１６マウスメラノーマを用いたメラニン生成抑制試験
対数増殖期にあるメラノーマをφ６０ｍｍ ｄｉｓｈに
：Ｘ １０４細胞播種し、最終濃度２〜１０ｍＭになる
ようにＤＬ−グリセリン酸を含むＥａｇｌｅｓ’ ＭＥ
Ｍ（１０％ＦＣＳを含む）を加え、３７℃、 ５％ＣＯ
□条件下にて培養し九また、比較試験として最終濃度が
５０〜１００μ鷲になるようにＬ−アスコルビン酸を加
えたものについても試験した。なお、 ＤＬ−グリセリ
ン酸、 Ｌ−アスコルビン酸処理時における培養液のｐ
Ｈは７．２〜７．４に調製したものを試験に供した。培
養３日後培養液を交換し、６日後細胞をｄｉｓｈから剥
離し、細胞数を計３すした後、細胞の沈澱にｌＯ％ＤＭ
ＳＯを含む０．ＩＮ ＮａＯＨをＩＸＬＱ６細胞／ｍｌ
となるように加え、その０Ｄ−ｙｉの測定値をメラニン
量とした。Trial example-1 Melanin production suppression test using B16 mouse melanoma Melanoma in the logarithmic growth phase was seeded with :X 104 cells in a φ60 mm dish, and Eagles' ME containing DL-glyceric acid was added to the final concentration of 2 to 10 mM.
M (containing 10% FCS) was added at 37°C, 5% CO
In addition, as a comparative test, L-ascorbic acid was added to the culture at a final concentration of 50 to 100 μm. In addition, p of the culture solution during treatment with DL-glyceric acid and L-ascorbic acid
H was prepared to 7.2 to 7.4 and used in the test. After 3 days of culture, the culture medium was replaced, and after 6 days, the cells were detached from the dish, and after a total of 3 cells, 10% DM was added to the cell pellet.
0 including SO. IN NaOH IXLQ6 cells/ml
The measured value of 0D-yi was taken as the amount of melanin.
その給気 表１に示すようにグリセリン酸は細胞毒性が
なく、濃度依存的にメラノーマのメラニン生成を抑制し
１′−Ｌ−アスコルビン酸は０．２ｍＭ以上の濃度にお
いて細胞毒性が強く、０．２ｍＭ以下でも効果が認めら
れなかった
以下余白
表１
メラニン生成抑制試験
ン酸 ０．２０ １．４２±０．１０実験例２
美白試験
シミ、ソバカス、 日焼は等の症状を訴える被験者１０
名に対して案施例２に示したクリームを顔面右側に一日
二回ずつ、−最高３力月まで連続上布し、効果を観察し
た。また、対照として実施例２の処方からグリセリン酸
を除いたクリーム（比較例２）を同様に顔面左側に連続
上布した。効果の判定は： 変わらない ＋： うすく
なった＋十： はとんど消えたの３段階とじた
その結果 表２に示すように７０％（１０名中７名）に
効果が見られた。比較例２のクリームには全く効果が認
められなかった。Air supply As shown in Table 1, glyceric acid is not cytotoxic and suppresses melanin production in melanoma in a concentration-dependent manner, and 1'-L-ascorbic acid is highly cytotoxic at concentrations of 0.2mM or higher; No effect was observed even at 2mM or less Table 1: Melanin production suppression test Honic acid 0.20 1.42 ± 0.10 Experimental example 2 Whitening test Subject 10 complaining of symptoms such as age spots, freckles, sunburn, etc.
The cream shown in Example 2 was applied to the right side of the face twice a day for up to 3 months, and the effect was observed. Further, as a control, a cream (Comparative Example 2) in which glyceric acid was removed from the formulation of Example 2 was applied continuously on the left side of the face in the same manner. The evaluation of the effect was: No change +: Fainted + 10: Almost disappeared As shown in Table 2, 70% (7 out of 10 patients) showed an effect. No effect was observed in the cream of Comparative Example 2.
表２
美白試験
実験例３
熱安定性試験
グリセリン酸の熱安定性を明らかにするために、実験例
１と同様の方法を用いて、＋００°Ｃで４時貨処理した
グリセリン酸のメラニン生成抑制作用を試験した。その
結果、抑制作用に差は認められず、また熱によって異臭
を発することもなく、安定性のよいものであった。Table 2 Whitening test Experimental example 3 Thermal stability test In order to clarify the thermal stability of glyceric acid, the same method as in Experimental example 1 was used to inhibit melanin production of glyceric acid treated at +00°C for 4 hours. The effect was tested. As a result, no difference was observed in the inhibitory effect, no off-odor was emitted by heat, and the product had good stability.
以上のように、本発明に使用するグリセリン酸は顕著な
美白効果を有し、保湿性、安定性にも優れている一方、
無臭である。また、グリセリン酸の塩においても同様の
効果が得られた。As described above, the glyceric acid used in the present invention has a remarkable whitening effect, and has excellent moisturizing properties and stability.
It is odorless. Similar effects were also obtained with glyceric acid salts.
Claims (1)
合することを特徴とする新規美白化粧料。A novel whitening cosmetic product characterized by containing glyceric acid and/or its salt as an active ingredient.
Priority Applications (1)
| Application Number | Priority Date | Filing Date | Title |
|---|---|---|---|
| JP24050190A JP2936233B2 (en) | 1990-09-10 | 1990-09-10 | New whitening cosmetics |
Applications Claiming Priority (1)
| Application Number | Priority Date | Filing Date | Title |
|---|---|---|---|
| JP24050190A JP2936233B2 (en) | 1990-09-10 | 1990-09-10 | New whitening cosmetics |
Publications (2)
| Publication Number | Publication Date |
|---|---|
| JPH04120008A true JPH04120008A (en) | 1992-04-21 |
| JP2936233B2 JP2936233B2 (en) | 1999-08-23 |
Family
ID=17060456
Family Applications (1)
| Application Number | Title | Priority Date | Filing Date |
|---|---|---|---|
| JP24050190A Expired - Fee Related JP2936233B2 (en) | 1990-09-10 | 1990-09-10 | New whitening cosmetics |
Country Status (1)
| Country | Link |
|---|---|
| JP (1) | JP2936233B2 (en) |
Cited By (4)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| US6076284A (en) * | 1994-03-18 | 2000-06-20 | Ballet Makers, Inc. | Shoe with split sole and mid-section reinforcement |
| CN100459975C (en) * | 2002-10-14 | 2009-02-11 | 雷梅朵有限公司 | Enhancement of alcohol metabolism |
| EP2332899A1 (en) | 2009-12-10 | 2011-06-15 | Rigas Tehniska universitate | The method for selective production of glyceric acid |
| EP2606968A2 (en) | 2011-12-23 | 2013-06-26 | Rigas Tehniska universitate | Process for the preparation of lactic acid from glycerol |
-
1990
- 1990-09-10 JP JP24050190A patent/JP2936233B2/en not_active Expired - Fee Related
Cited By (4)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| US6076284A (en) * | 1994-03-18 | 2000-06-20 | Ballet Makers, Inc. | Shoe with split sole and mid-section reinforcement |
| CN100459975C (en) * | 2002-10-14 | 2009-02-11 | 雷梅朵有限公司 | Enhancement of alcohol metabolism |
| EP2332899A1 (en) | 2009-12-10 | 2011-06-15 | Rigas Tehniska universitate | The method for selective production of glyceric acid |
| EP2606968A2 (en) | 2011-12-23 | 2013-06-26 | Rigas Tehniska universitate | Process for the preparation of lactic acid from glycerol |
Also Published As
| Publication number | Publication date |
|---|---|
| JP2936233B2 (en) | 1999-08-23 |
Similar Documents
| Publication | Publication Date | Title |
|---|---|---|
| JP3638832B2 (en) | Cosmetic and / or dermatological composition comprising at least one mulberry extract, at least one seaweed extract and at least one salicylic acid derivative | |
| JP2000095663A (en) | Agent for external use containing plant extract | |
| JPH09157153A (en) | Preparation for external use for skin | |
| JPH06157278A (en) | Skin external preparation for acne vulgaris | |
| JPH04120008A (en) | New beautifying cosmetic | |
| JPH0812560A (en) | Skin external preparation | |
| JPH1029924A (en) | Antiaging agent | |
| JPH1029927A (en) | Antiaging agent | |
| JP2780803B2 (en) | External preparation for skin | |
| JP4842550B2 (en) | Tyrosinase activity inhibitor, melanin production inhibitor, and skin whitening external preparation | |
| JP4349809B2 (en) | Collagen production promoter | |
| JP2002037716A (en) | Kaurenes-containing composition, hair-growing agent and skin care agent | |
| JP3380261B2 (en) | Cosmetics | |
| JP2005206521A (en) | Antimicrobial agent | |
| JPH07242542A (en) | Cosmetic | |
| JPH07149622A (en) | Beautifying and whitening preparation | |
| JPH03157311A (en) | Cosmetic for common acne | |
| JPS63183518A (en) | Composition for hair | |
| JPH10265364A (en) | Lipase inhibitor and external preparation for skin for pimple | |
| JPH04187619A (en) | Melanogenesis inhibitor and cosmetics | |
| JPH03127712A (en) | Agent for external application | |
| JPH0441409A (en) | Whitening cosmetic | |
| JP2002356414A (en) | Skin whitening preparation | |
| JPH01121206A (en) | Skin beautifying cosmetic | |
| KR20040057413A (en) | Cosmetic Product containing Ascorbic Acid-2-Glucoside |
Legal Events
| Date | Code | Title | Description |
|---|---|---|---|
| S111 | Request for change of ownership or part of ownership |
Free format text: JAPANESE INTERMEDIATE CODE: R313111 |
|
| R350 | Written notification of registration of transfer |
Free format text: JAPANESE INTERMEDIATE CODE: R350 |
|
| R250 | Receipt of annual fees |
Free format text: JAPANESE INTERMEDIATE CODE: R250 |
|
| LAPS | Cancellation because of no payment of annual fees |